Five PubMed papers to open first: small-cell lung cancer, narcolepsy, COPD, stroke, and thalassaemia
A ranked 10-minute triage of five papers entered in PubMed from September 8-15, 2026, led by phase 3 results in relapsed small-cell lung cancer, narcolepsy type 1, COPD exacerbations, acute ischemic stroke, and transfusion-dependent thalassaemia.
This issue covers the papers that entered PubMed between September 8 and September 15, 2026, using each record's PubMed entry date. All five are phase 3 randomized trials in journals at the top of the impact tiers. Their early citation counts are still too young to rank them: as of September 15, four of the five had no cited-by works, one had one, and one had two. The order below rests on the strength of the randomized evidence and on how directly each result changes a treatment decision.
At a glance
| Rank | Paper | Journal and tier | Design and sample | Primary result | Early cited-by signal |
|---|---|---|---|---|---|
| 1 | Tambotatug pelitecan for relapsed small-cell lung cancer 1 | The New England Journal of Medicine; very high impact tier | Phase 3, open-label, randomized, multicentre trial; 451 patients | Median overall survival 13.3 vs 9.4 months; hazard ratio 0.46, 95% CI 0.35-0.62, P<.001 | 0 2 |
| 2 | Oveporexton for narcolepsy type 1 3 | The New England Journal of Medicine; very high impact tier | Two phase 3, randomized, placebo-controlled trials; 168 and 105 patients | Mean sleep latency on the Maintenance of Wakefulness Test changed by 14.3 to 19.8 minutes vs -0.4 to -0.8 minutes with placebo; adjusted P<.001 | 2 4 |
| 3 | Tozorakimab for COPD exacerbations 5 | The New England Journal of Medicine; very high impact tier | Two replicate phase 3 randomized trials; 877 and 873 patients | Annualized exacerbation rate 1.41 vs 2.00 (rate ratio 0.70, 95% CI 0.58-0.85) in OBERON and 1.44 vs 2.03 (rate ratio 0.71, 95% CI 0.59-0.84) in TITANIA; P<.001 | 0 6 |
| 4 | Loberamisal for acute ischemic stroke 7 | JAMA; very high impact tier | Phase 3, double-blind, randomized, placebo-controlled trial at 32 hospitals in China; 997 patients analyzed | Modified Rankin Scale score 0 to 1 at 90 days in 69.7% vs 56.3%; relative risk 1.24, 95% CI 1.12-1.36 | 0 8 |
| 5 | Mitapivat for transfusion-dependent thalassaemia 9 | The Lancet; very high impact tier | Phase 3, double-blind, randomized, placebo-controlled trial in 19 countries; 258 patients | Transfusion reduction response in 30% vs 13%; adjusted difference 18 percentage points, 95% CI 8-27, P=.0003 | 1 10 |
1. Tambotatug pelitecan for small-cell lung cancer after platinum therapy
Journal and impact tier: The New England Journal of Medicine, very high impact tier. PubMed entered the paper on September 14, 2026, under PMID 42734213. 1
Author and affiliation: First author Yuanyuan Zhao works in the Department of Medical Oncology at the Sun Yat-sen University Cancer Center in Guangzhou, as does senior author Li Zhang; the center's state key laboratory and provincial cancer research center share the affiliation. 1
Design, setting, and sample: TAISHAN-302 is a phase 3, open-label, randomized, multicentre trial of tambotatug pelitecan, an antibody-drug conjugate that targets B7-H3, against topotecan in patients whose small-cell lung cancer had progressed after first-line platinum-based therapy. The trial randomized 451 patients, 225 to tambotatug pelitecan and 226 to topotecan, and the paper reports the prespecified interim analysis. The registry lists MediLink Therapeutics (Suzhou) as sponsor. 11
Primary endpoint and quantitative result: The primary endpoint was overall survival. Median overall survival was 13.3 months with tambotatug pelitecan versus 9.4 months with topotecan, with the upper bound of the confidence interval not estimable; stratified hazard ratio for death 0.46, 95% CI 0.35-0.62, P<.001. Median progression-free survival was 7.4 versus 2.8 months (hazard ratio 0.29, 95% CI 0.23-0.37, P<.001), and a confirmed objective response occurred in 59.1% versus 9.7%. Adverse events of grade 3 or higher were less frequent with tambotatug pelitecan, at 55.4% versus 77.9%. 1
Why it matters: Topotecan has been a standard second-line option for relapsed small-cell lung cancer, a setting where randomized gains have been hard to produce. This trial puts a new antibody-drug conjugate ahead of it on overall survival, progression-free survival, and objective response while reporting fewer grade 3 or higher adverse events, which is the combination a treatment decision in this population turns on. 1
Limitation and evidence boundary: The reported numbers come from a prespecified interim analysis of an open-label trial, so the survival estimate can still move as follow-up matures; the registry lists primary completion in December 2027. The result applies to patients who progressed after first-line platinum-based therapy and were eligible for topotecan, which is the population the trial enrolled. 1
Funding or disclosure: The paper lists the Innovative Drug Research and Development National Science and Technology Major Project and MediLink Therapeutics as funders, and registers the trial as NCT06612151. 1
2. Oveporexton for narcolepsy type 1
Journal and impact tier: The New England Journal of Medicine, very high impact tier. PubMed entered the paper on September 9, 2026, under PMID 42714024. 3
Author and affiliation: First author Yves Dauvilliers leads the Sleep-Wake Disorders Center in the Department of Neurology at Gui-de-Chauliac Hospital, Centre Hospitalier Universitaire de Montpellier, in France; senior author Giuseppe Plazzi is at the IRCCS Istituto delle Scienze Neurologiche di Bologna in Italy. 3
Design, setting, and sample: Two phase 3, randomized, placebo-controlled trials tested oveporexton, an oral orexin receptor 2-selective agonist, over 12 weeks in participants aged 16 to 70 with narcolepsy type 1. The First Light trial randomized 168 participants in a 3:3:2 ratio to oveporexton 1 mg, oveporexton 2 mg, or placebo twice daily; the Radiant Light trial randomized 105 participants 2:1 to oveporexton 2 mg or placebo, so the 1 mg comparison rests on First Light alone. First Light ran at 53 sites across 11 countries and Radiant Light at 28 sites across 11 countries, with Takeda as sponsor of both. 1213
Primary endpoint and quantitative result: The primary endpoint was the change from baseline to week 12 in mean sleep latency on the Maintenance of Wakefulness Test, a 0-to-40-minute scale on which 20 minutes or more is normal. Mean sleep latency improved by 14.3 to 19.8 minutes with oveporexton, against a worsening of 0.4 to 0.8 minutes with placebo (adjusted P<.001 for every comparison). The Epworth Sleepiness Scale total score changed by -9.7 to -11.8 with oveporexton versus -1.5 to -1.7 with placebo, and the median weekly cataplexy rate fell 79.0% to 88.8% versus 27.7% to 39.1%, both with adjusted P<.001. Adverse events occurred in 86% to 89% of participants taking oveporexton and 43% to 54% of those taking placebo; increased urinary frequency and transient insomnia were the most common. 3
Why it matters: Narcolepsy type 1 follows the loss of orexin-producing neurons, and oveporexton supplies the missing signal by mouth at orexin receptor 2. The two trials reproduced each other on sleep latency and cataplexy, and the cataplexy reductions arrive alongside the sleepiness results in the same 12-week treatment period. 3
Limitation and evidence boundary: Both trials covered 12 weeks of treatment, so the reported efficacy and safety describe that period and the longer-term profile remains open. The safety difference is part of the result: 86% to 89% of participants on oveporexton reported adverse events, most often increased urinary frequency and transient insomnia, against 43% to 54% on placebo. 3
Funding or disclosure: Takeda Development Center Americas funded the trials, registered as NCT06470828 and NCT06505031. 3
3. Tozorakimab for COPD exacerbations
Journal and impact tier: The New England Journal of Medicine, very high impact tier. PubMed entered the paper on September 8, 2026, under PMID 42708515. 5
Author and affiliation: First author Frank C. Sciurba is at the University of Pittsburgh's division of Pulmonary, Allergy, Critical Care, and Sleep Medicine; the final author, Ioannis Psallidas, is in AstraZeneca's respiratory and immunology clinical development group in Boston. 5
Design, setting, and sample: OBERON and TITANIA are two replicate phase 3 trials of subcutaneous tozorakimab, a monoclonal antibody against interleukin-33, given at 300 mg every four weeks for 52 weeks as an add-on to standard inhaled maintenance therapy. Both enrolled current and former smokers with COPD and a history of exacerbations in the previous year, and neither applied any eligibility criterion based on blood eosinophil count. The published analyses cover 877 patients in OBERON, 446 on tozorakimab and 431 on placebo, and 873 patients in TITANIA, 438 and 435. AstraZeneca sponsors both trials. 1415
Primary endpoint and quantitative result: The primary endpoint was the annualized rate of moderate or severe exacerbations over 52 weeks among former smokers, and the first key secondary endpoint was the same rate in the overall population. Among former smokers the rate was 1.34 with tozorakimab versus 1.90 with placebo in OBERON (rate ratio 0.71, 95% CI 0.57-0.88, P=.002) and 1.37 versus 2.07 in TITANIA (rate ratio 0.66, 95% CI 0.55-0.80, P<.001). In the overall population the rate was 1.41 versus 2.00 in OBERON (rate ratio 0.70, 95% CI 0.58-0.85, P<.001) and 1.44 versus 2.03 in TITANIA (rate ratio 0.71, 95% CI 0.59-0.84, P<.001). Adverse events were reported by 70.4% of patients on tozorakimab and 77.2% on placebo in OBERON, and by 80.1% and 79.8% in TITANIA. 5
Why it matters: Two replicate trials pointing the same way on the same endpoint is the evidence shape COPD treatment decisions rest on. Tozorakimab cut exacerbations by roughly 30% on top of inhaled maintenance therapy, in both the former-smoker population that carried the primary endpoint and the overall population of current and former smokers, and the trials selected patients without any eosinophil threshold. 5
Limitation and evidence boundary: The result describes patients who had already had an exacerbation in the previous year while on stable inhaled maintenance therapy, which is the population enrolled. The overall-population findings are secondary to the former-smoker primary endpoint, and the paper reports no outcome beyond the 52-week treatment period. 5
Funding or disclosure: AstraZeneca funded both trials, registered as NCT05166889 (OBERON) and NCT05158387 (TITANIA). 5
4. Loberamisal for acute ischemic stroke
Journal and impact tier: JAMA, very high impact tier. PubMed entered the paper on September 10, 2026, under PMID 42721021. 7
Author and affiliation: First author Shuya Li and senior author Yongjun Wang are both in the Department of Neurology at Beijing Tiantan Hospital, Capital Medical University. 7
Design, setting, and sample: LAIS was a multicentre, double-blind, randomized, placebo-controlled phase 3 trial at 32 hospitals in China, testing intravenous loberamisal, a small molecule that acts on the postsynaptic density 95 pathway and the alpha2-GABAA receptor. Adults aged 18 to 80 with acute ischemic stroke, a baseline National Institutes of Health Stroke Scale score of 7 to 20, no prestroke disability, and presentation within 48 hours of symptom onset were randomly assigned 1:1 to loberamisal 40 mg or placebo once daily for 10 days alongside standard stroke care. Enrollment ran from July 24 to December 7, 2024, and 997 of 998 randomized participants received at least one dose of study drug, 502 on loberamisal and 495 on placebo. Beijing Tiantan Hospital is the sponsor, with Neurodawn Pharmaceutical as collaborator. 16
Primary endpoint and quantitative result: The primary outcome was a modified Rankin Scale score of 0 to 1 at 90 days, which marks a full functional outcome. 350 of 502 participants on loberamisal (69.7%) reached that outcome, against 279 of 495 on placebo (56.3%), for a relative risk of 1.24 (95% CI 1.12-1.36) and a risk difference of 13.28 percentage points (95% CI 7.24-19.32). Adverse events occurred in 87.8% versus 88.7% of the two groups, serious adverse events in 8.6% versus 10.7%, and all-cause mortality in 1.2% versus 2.0%. 7
Why it matters: The paper opens on the shortage of effective neuroprotective and neuroreparative therapies for acute ischemic stroke, and loberamisal adds a pharmacological approach to a treatment field dominated by reperfusion. The trial dosed patients up to 48 hours after symptom onset, which is a wider window than reperfusion strategies use. 7
Limitation and evidence boundary: All 998 participants were enrolled at hospitals in China, over a five-month period. The investigators state that further studies are needed to validate the findings and to establish whether the benefit extends to a broader patient population; the reported outcome covers function at 90 days. 7
Funding or disclosure: The PubMed record carries no funding statement. The trial registry lists Beijing Tiantan Hospital as sponsor and Neurodawn Pharmaceutical as collaborator, registers the trial as NCT06517173, and the paper reports no conflicts of interest from its authors. 716
5. Mitapivat for transfusion-dependent thalassaemia
Journal and impact tier: The Lancet, very high impact tier; the paper appears in volume 408, issue 10559, pages 1010-1018. PubMed entered it on September 10, 2026, under PMID 42721980. 9
Author and affiliation: First author Maria Domenica Cappellini is at the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, and senior author Antonis Kattamis is at the National and Kapodistrian University of Athens. 9
Design, setting, and sample: ENERGIZE-T was a double-blind, randomized, placebo-controlled phase 3 trial across 19 countries in North America, Europe, Asia-Pacific, South America, and the Middle East. Adults with transfusion-dependent alpha- or beta-thalassaemia were randomly allocated 2:1 to oral mitapivat 100 mg or placebo twice daily for 48 weeks. Of 258 patients randomized, the full analysis set held 171 on mitapivat and 87 on placebo, and 238 completed the double-blind treatment period. Agios Pharmaceuticals is the sponsor. 17
Primary endpoint and quantitative result: The primary endpoint was transfusion reduction response, defined as a reduction of at least 50% in transfused red-cell units together with a reduction of at least two units within any consecutive 12-week period through week 48. The response occurred in 52 of 171 patients on mitapivat (30%) and 11 of 87 on placebo (13%), an adjusted difference of 18 percentage points (95% CI 8-27, P=.0003). Adverse events were reported by 90% of patients on mitapivat and 84% on placebo, serious adverse events by 11% and 15%, and 6% versus 1% discontinued study treatment because of adverse events. No deaths were reported. 9
Why it matters: The paper frames the unmet need as no disease-modifying therapy for transfusion-dependent alpha-thalassaemia and no oral disease-modifying therapy for the beta form. Mitapivat, an oral pyruvate kinase activator, cut transfusion requirements by half or more in about one patient in three over 48 weeks, against about one in eight on placebo, and the trial's authors present it as the first oral disease-modifying option for this population. 9
Limitation and evidence boundary: The primary endpoint is a transfusion-burden measure, and the trial's reported outcomes stop at 48 weeks of treatment plus a safety follow-up about four weeks after the last dose; iron overload, organ complications, and survival lie outside the endpoints. The enrolled population was adults aged 18 and over with the transfusion-dependent forms of either alpha- or beta-thalassaemia. 9
Funding or disclosure: Agios Pharmaceuticals funded the trial, registered as NCT04770779; the first author reports honoraria from Agios, and several co-authors report research funding or advisory fees from Agios and other companies, with the declarations listed in full alongside the record. 9
What to open first
- Second-line small-cell lung cancer: Open TAISHAN-302 if your question is how an anti-B7-H3 antibody-drug conjugate compares with topotecan on overall survival in patients who have progressed on platinum. 1
- Narcolepsy type 1: Open the oveporexton trials if your question is how much an oral orexin receptor 2 agonist moves sleep latency, daytime sleepiness, and cataplexy over 12 weeks, and what it costs in adverse events. 3
- COPD: Open OBERON and TITANIA if your question is whether an anti-interleukin-33 antibody lowers exacerbations in patients who already take inhaled maintenance therapy. 5
- Acute ischemic stroke: Open LAIS if your question is whether intravenous loberamisal started within 48 hours improves 90-day function. 7
- Transfusion-dependent thalassaemia: Open ENERGIZE-T if your question is how many adults on oral mitapivat halve their transfusion requirement. 9
The five papers cover a second-line lung-cancer comparison, a two-trial narcolepsy program, two replicate COPD trials, a stroke neuroprotectant, and the first oral disease-modifying therapy for transfusion-dependent thalassaemia. Each reports what happened inside its enrolled population, and the boundary stated in each entry above marks how far that answer reaches.
References
- 1Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
pubmed.ncbi.nlm.nih.gov
- 2OpenAlex record for the TAISHAN-302 paper
openalex.org
- 3Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials
pubmed.ncbi.nlm.nih.gov
- 4OpenAlex record for the oveporexton trials
openalex.org
- 5Tozorakimab to Prevent COPD Exacerbations
pubmed.ncbi.nlm.nih.gov
- 6OpenAlex record for the tozorakimab trials
openalex.org
- 7Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial
pubmed.ncbi.nlm.nih.gov
- 8OpenAlex record for the LAIS trial
openalex.org
- 9
- 10OpenAlex record for the ENERGIZE-T trial
openalex.org
- 11
- 12A Study of TAK-861 for the Treatment of Narcolepsy Type 1 (First Light)
clinicaltrials.gov
- 13A Study of TAK-861 in People With Narcolepsy Type 1 (Radiant Light)
clinicaltrials.gov
- 14
- 15
- 16Y-3 for Injection in the Treatment of Acute Ischemic Stroke (LAIS)
clinicaltrials.gov
- 17
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.